• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

p53 mutations in chondrosarcoma.

作者信息

Terek R M, Healey J H, Garin-Chesa P, Mak S, Huvos A, Albino A P

机构信息

Department of Orthopaedics, Rhode Island Hospital and Providence Veterans Administration Medical Center, Providence, USA.

出版信息

Diagn Mol Pathol. 1998 Feb;7(1):51-6. doi: 10.1097/00019606-199802000-00009.

DOI:10.1097/00019606-199802000-00009
PMID:9646035
Abstract

Chondrosarcoma is a primary bone tumor that has several different grades and variants. We evaluated 48 chondrosarcomas for p53 overexpression and p53 mutations. p53 expression was evaluated with immunohistochemistry using monoclonal antibodies PAb421, PAb1801, and PAb240. p53 mutations were identified with single-strand conformational polymorphism (SSCP) and DNA sequencing in selected cases. Immunohistochemistry revealed nuclear staining with PAb421 and PAb1801 in the spindle cell portion of one dedifferentiated chondrosarcoma. SSCP analysis was abnormal only in the case with positive immunostaining and localized the mutation to exons 7 and 8. DNA sequence analysis identified a point mutation of G to C in codon 276, resulting in an amino acid substitution of proline for alanine. This point mutation has been reported previously in other tumors but not in chondrosarcoma. Assimilation of our results with previous studies suggests that p53 mutations are present in a minority of chondrosarcomas but when present, are in higher grade chondrosarcomas and their variants.

摘要

相似文献

1
p53 mutations in chondrosarcoma.
Diagn Mol Pathol. 1998 Feb;7(1):51-6. doi: 10.1097/00019606-199802000-00009.
2
Possible association of p53 overexpression and mutation with high-grade chondrosarcoma.
Diagn Mol Pathol. 1993 Dec;2(4):257-63.
3
Overexpression of p53 protein in squamous cell carcinomas of head and neck without apparent gene mutations.在无明显基因突变的头颈部鳞状细胞癌中p53蛋白的过表达。
Diagn Mol Pathol. 1994 Jun;3(2):83-92. doi: 10.1097/00019606-199406000-00004.
4
Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma.乳腺癌中p53免疫染色模式与基因序列突变之间的相关性
Diagn Mol Pathol. 1996 Sep;5(3):187-93. doi: 10.1097/00019606-199609000-00007.
5
Overexpression of p53 and absent genetic mutation in clear cell chondrosarcoma.透明细胞软骨肉瘤中p53过表达且无基因突变。
Int J Oncol. 2001 Aug;19(2):353-7. doi: 10.3892/ijo.19.2.353.
6
p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas.p53表达及其与骨和软组织肉瘤中DNA改变的关系。
Br J Cancer. 1993 Dec;68(6):1134-9. doi: 10.1038/bjc.1993.493.
7
Overexpression of p53 and rare genetic mutation in mesenchymal chondrosarcoma.p53在间充质软骨肉瘤中的过表达及罕见基因突变
Oncol Rep. 2000 Sep-Oct;7(5):1041-7. doi: 10.3892/or.7.5.1041.
8
Altered p53 is associated with aggressive behavior of chondrosarcoma: a long term follow-up study.p53改变与软骨肉瘤的侵袭性行为相关:一项长期随访研究。
Cancer. 1998 Dec 1;83(11):2324-34. doi: 10.1002/(sici)1097-0142(19981201)83:11<2324::aid-cncr12>3.0.co;2-u.
9
Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma.杂合性缺失和DNA倍体表明外周型和中央型软骨肉瘤起源存在不同的遗传机制。
Genes Chromosomes Cancer. 1999 Nov;26(3):237-46.
10
Mutation of p53 with loss of heterozygosity in the osteosarcomatous component of a dedifferentiated chondrosarcoma.去分化软骨肉瘤的骨肉瘤成分中p53突变伴杂合性缺失。
Virchows Arch. 2000 May;436(5):494-7. doi: 10.1007/s004280050478.

引用本文的文献

1
Advances in the Molecular Biology of Chondrosarcoma for Drug Discovery and Precision Medicine.用于药物研发和精准医学的软骨肉瘤分子生物学进展
Cancers (Basel). 2025 Aug 19;17(16):2689. doi: 10.3390/cancers17162689.
2
Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.常规和去分化软骨肉瘤的临床-基因组分析显示 TP53 突变与更差的预后相关。
Clin Cancer Res. 2023 Dec 1;29(23):4844-4852. doi: 10.1158/1078-0432.CCR-23-1703.
3
Dedifferentiated Chondrosarcoma: Diagnostic Controversies and Emerging Therapeutic Targets.
去分化软骨肉瘤:诊断争议与新兴治疗靶点
Curr Oncol Rep. 2023 Oct;25(10):1117-1126. doi: 10.1007/s11912-023-01441-1. Epub 2023 Aug 21.
4
Dedifferentiated Chondrosarcoma from Molecular Pathology to Current Treatment and Clinical Trials.去分化软骨肉瘤:从分子病理学到当前治疗及临床试验
Cancers (Basel). 2023 Aug 1;15(15):3924. doi: 10.3390/cancers15153924.
5
Primary Chondrosarcoma in L-shaped Crossed Fused Renal Ectopia Coexisting with Papillary Urothelial Carcinoma in Urinary Bladder - An Enigmatic Entity with Poor Prognosis.L形交叉融合性肾异位并存膀胱乳头状尿路上皮癌中的原发性软骨肉瘤——一种预后不良的罕见实体
J Kidney Cancer VHL. 2022 Jan 1;9(1):9-14. doi: 10.15586/jkcvhl.v9i1.162. eCollection 2022.
6
Dedifferentiated Central Chondrosarcoma: A Clinical, Histopathological, and Immunohistochemical Analysis of 57 Cases.去分化中央型软骨肉瘤:57例临床、组织病理学及免疫组织化学分析
Front Med (Lausanne). 2021 Sep 23;8:746909. doi: 10.3389/fmed.2021.746909. eCollection 2021.
7
Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to Immunophenotype.软骨肉瘤的生物学异质性:从(表观)遗传学、干性及失调信号传导到免疫表型
Cancers (Basel). 2021 Mar 15;13(6):1317. doi: 10.3390/cancers13061317.
8
Difficulties of Management of Multiple Synchronous Bone Tumors in Li-Fraumeni Syndrome.李-弗劳梅尼综合征中多发性同步骨肿瘤的管理难点
Case Rep Orthop. 2019 Nov 13;2019:8732089. doi: 10.1155/2019/8732089. eCollection 2019.
9
Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes.软骨肉瘤细胞中的放疗抗性;与细胞周期相关基因改变的可能关联。
Clin Sarcoma Res. 2019 May 28;9:9. doi: 10.1186/s13569-019-0119-0. eCollection 2019.
10
Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway.软骨肉瘤代谢组学的探索;mTOR通路作为一条重要的促生存通路。
J Bone Oncol. 2019 Jan 29;15:100222. doi: 10.1016/j.jbo.2019.100222. eCollection 2019 Apr.